Adjuvant role for cell death during chemo- and radiotherapy of cancer?

Expert Review of Clinical Immunology

Volumn 4, Issue 1, 2008, Pages 27-32

  Rovere Querini, Patrizia ^a   Castiglioni, Alessandra ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Antigen presentation; Cell death; HMGB1; Immunosurveillance; Response to chemotherapy and radiotherapy; Toll like receptors; Tumor immunology

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; IRINOTECAN; NUCLEAR PROTEIN; OXALIPLATIN; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ACTIVATION; CELL DEATH; CELL MATURATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXICITY; DENDRITIC CELL; DNA POLYMORPHISM; DRUG EFFICACY; FIBROSARCOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PANCREAS ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIATION DOSE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNOLOGY; X IRRADIATION;

EID: 46149117538     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.1.27     Document Type: Article

References (24)

1. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007).
2. Ronchetti A, Rovere P, lezzi G et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163, 130-136 (1999).
3. Rovere P. Vallinoto C, Bondanza A et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol. 161, 4467-4471 (1998).
4. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
5. + T cells. Nat. Immunol. 2, 1010-1017 (2001).
6. Ellerman JE, Brown CK, de Vera M et al. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res. 13, 2836-2848 (2007).
7. Rovere-Querini P, Capobianco A, Scaffidi P et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5, 825-830 (2004).
8. Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691-1701 (2005).
9. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359-365 (2005).
10. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220, 35-46 (2007).
11. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002).
12. Gardella S, Andrei C, Ferrera D et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995-1001 (2002)
13. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 255, 320-331 (2004).
14. Palumbo R, Galvez BG, Pusterla T et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activation. J. Cell Biol. 179, 33-40 (2007).
15. Messmer D, Yang H, Telusma G et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307-313 (2004).
16. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949-955 (2001).
17. Orlova VV, Choi EY, Xie C et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26, 1129-1139 (2007).
18. Park JS, Gamboni-Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. 290, C917-C924 (2006).
19. Yu M, Wang H, Ding A et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26, 174-179 (2006).
20. Bender B, Jiang Z, Georgel P et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24, 353-389 (2006).
21. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007).
22. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496 (2007).
23. Pisetsky DS. Autoimmunity: the nuclear arsenal of autoimmunity. Immunol Cell Biol. 85, 344-345 (2007).
24. Galluzzi L, Maiuri MC, Vitale I et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 14, 1237-1243 (2007).